placebo for risankizumab IV

DRUG2 trials

Conditions

Crohn's Disease

Phase 3

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

CompletedNCT03104413

AbbVieCrohn's Disease

Start: 2017-12-18End: 2021-05-19Updated: 2022-06-14

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Active, not recruitingNCT03105102

AbbVieCrohn's Disease

Start: 2018-04-09End: 2026-05-31Updated: 2025-08-14

2025-02-034 citations

DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension

Journal of Crohn s and Colitis2025-01-011 citations

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

Journal of Crohn s and Colitis2024-11-012 citations

Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease

Gastro Hep Advances2024-09-061 citations

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.

2024-03-074 citations

DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

Journal of Crohn s and Colitis2024-01-017 citations

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

Journal of Crohn s and Colitis2024-01-01

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial

Journal of Crohn s and Colitis2023-10-0413 citations

Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Journal of Gastroenterology and Hepatology2023-10-0315 citations

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.

2023-06-2710 citations

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.

2023-03-1410 citations

P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease

Journal of Crohn s and Colitis2023-01-30

S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn’s Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy

The American Journal of Gastroenterology2022-12-011 citations

S87 Risankizumab Maintenance Therapy Is Effective in Patients Achieving CDAI Clinical Response With Induction Therapy: Post Hoc Analysis From FORTIFY

The American Journal of Gastroenterology2022-12-01

Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial

Rheumatology and Therapy2022-08-0514 citations

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.

2022-05-01264 citations

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.

2022-05-01215 citations

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Journal of the Canadian Association of Gastroenterology2022-02-21

OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Journal of Crohn s and Colitis2022-01-017 citations

DOP85 Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapy

Journal of Crohn s and Colitis2022-01-014 citations

11 more papers not shown

placebo for risankizumab IV

Sponsors

Conditions

Phase 3

Related Papers